文献速递肝胆胰外科围术期管理与 ERAS

腹腔镜左胰腺切除术治疗放化疗后胰腺导管腺癌安全性与开腹相当

Laparoscopic left pancreatectomy is safe for the treatment of pancreatic ductal adenocarcinoma treated by chemoradiotherapy compared to open left pancreatectomy: a single-center retrospective study.
PubMed 文献 · Surg Endosc · 2026-08-21

单中心回顾性研究纳入2012至2024年间57例接受新辅助放化疗后行左胰腺切除术的胰腺导管腺癌患者,其中腹腔镜22例、开腹35例。腹腔镜组术中出血、手术时间和住院时间均优于开腹组,而Clavien III-IV并发症、死亡率、B/C级胰瘘、肿瘤大小、淋巴结清扫数、R0切除率及3年和5年生存率两组相当。结论认为新辅助放化疗不损害腹腔镜手术的优势。

要点

  • 新辅助放化疗后腹腔镜左胰腺切除术出血更少、手术时间和住院时间更短。
  • 两组Clavien III-IV并发症、死亡率、B/C级胰瘘及R0切除率无显著差异。
  • 两组3年和5年总生存及无病生存可比,肿瘤学结局相当。

核心结论

  • 新辅助放化疗不损害腹腔镜左胰腺切除术的优势,其手术和肿瘤学结局与开腹左胰腺切除术相当。

研究设计与样本

  • 单中心回顾性队列研究,纳入2012至2024年间接受新辅助放化疗后行左胰腺切除术的胰腺导管腺癌患者57例,其中腹腔镜组22例(39%)、开腹组35例(61%)。

主要发现

  • 腹腔镜组较开腹组中位出血量更少(100 vs. 300 mL,p=0.002),中位手术时间更短(210 vs. 255 min,p=0.003),中位住院时间更短(8 vs. 14天,p<0.001)。
  • 两组Clavien III-IV并发症发生率(0 vs. 9%,p=0.276)、死亡率(0% vs. 6%,p=0.518)和B/C级术后胰瘘发生率(0 vs. 3%,p=1.00)相似。
  • 两组中位肿瘤大小(25 vs. 21 mm,p=0.657)、中位淋巴结清扫数(15 vs. 21,p=0.185)和R0切除率(均为86%,p=1.00)相似。
  • 两组3年和5年总生存及无病生存可比。

临床怎么用

  • 对于接受新辅助放化疗的胰体尾胰腺导管腺癌患者,腹腔镜左胰腺切除术可作为开腹手术的可行选择,不增加短期并发症或损害肿瘤学结局。

局限性

  • 单中心回顾性研究,样本量较小(57例),可能存在选择偏倚,结论需更大样本前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant chemoradiotherapy (NACRT) has become a standard in the treatment of borderline and locally advanced pancreatic ductal adenocarcinomas (PDAC). Left pancreatectomy (LP) is the procedure of choice for body and tail PDAC. Only a few data compare the outcomes of laparoscopic and open LP (LLP, OLP) after NACRT. METHODS: A monocentric retrospective cohort of patients who underwent LLP or OLP for PDAC after NACRT between 2012 and 2024. RESULTS: We included 57 patients, 22 LLP (39%) and 35 OLP (61%) with no difference regarding demographic characteristics. LLP compared to OLP showed less median blood loss (100 vs. 300 mL, p = 0.002), shorter median operative time (210 vs. 255 min, p = 0.003), and median length of stay (8 vs. 14 days, p < 0.001). Rates of Clavien III-IV complications (0 vs. 9%; p = 0.276), mortality (0% vs. 6%, p = 0.518) and grade B/C postoperative pancreatic fistula (0 vs. 3%; p = 1.00) were similar. Median tumor size (25 vs. 21 mm, p = 0.657), median number of harvested lymph nodes (15 vs. 21, p = 0.185), and R0 resection rate (86% for both, p = 1.00) were similar as well. Three-year and five-year overall and disease-free survival were comparable. CONCLUSION: NACRT does not seem to compromise the benefits of laparoscopic surgery as LLP has comparable surgical and oncological outcomes compared to OLP.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Vlasceanu A, Karam E, Aussilhou B, et al. Laparoscopic left pancreatectomy is safe for the treatment of pancreatic ductal adenocarcinoma treated by chemoradiotherapy compared to open left pancreatectomy: a single-center retrospective study. Surg Endosc. 2026. PMID: 42627533. doi:10.1007/s00464-026-12991-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。